CHMP Endorses AstraZeneca's (AZN) Enhertu in Lung Cancer
Data from a mid-stage study shows that treatment with AstraZeneca's (AZN) Enhertu achieved strong and durable tumor responses in certain non-small cell lung cancer patients.
Investors Heavily Search AstraZeneca PLC (AZN): Here is What You Need to Know
Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
EU recommends approval of AstraZeneca and Daiichi's drug for a type of lung cancer
AstraZeneca said on Friday the European Medicines Agency's human medicines committee recommended its and Daiichi Sankyo's Enhertu drug as a monotherapy to treat patient with a type of non-small cel...
AstraZeneca succession sickness demands urgent fix
Can a CEO be worth $9 billion? That's the question posed by the 4% fall in AstraZeneca's shares following an article stating boss Pascal Soriot may soon resign.
GSK opens new site in UK unlike rival AstraZeneca
GSK has opened a new £65 million drug factory in Hertfordshire in a move it said would enable rapid production of medicines developed through its research pipeline. In contrast to UK rival AstraZen...
AstraZeneca (AZN) Posts Upbeat Data on Lung Cancer Drug Combo
Data from a late-stage study shows that AstraZeneca's (AZN) Tagrisso combined with chemotherapy cut the risk of disease progression or death by 38% in certain lung cancer patients.
AstraZeneca bounces back from reports that CEO Soriot is eyeing exit
Shares in AstraZeneca PLC (LSE:AZN) have bounced back after falling on a report that chief executive Pascal Soriot is looking to step down, possibly as soon as next year. Following a steep 4.1% dr...
AstraZeneca's Tagrisso-chemo combo results raise bar for J&J cancer drug-analysts
Data released on Monday by AstraZeneca from a late-stage trial combining its blockbuster cancer drug Tagrisso with chemotherapy to treat a type of lung cancer raises the bar for Johnson & Johnson's...
AstraZeneca (AZN) Gets FDA CRL for Ultomiris in New Indication
AstraZeneca (AZN) said the CRL for Ultomiris for NMOSD indication does not raise any concerns about the efficacy and safety data from the study.
Here is What to Know Beyond Why AstraZeneca PLC (AZN) is a Trending Stock
Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors?
Veracyte's revenue sharply rose in the second quarter. The company is moving toward profitability.
More AstraZeneca drugs to be added to US IRA list, Barclays predicts
AstraZeneca PLC (LSE:AZN) faces several negative headwinds for US sales of some of its drugs from the new Inflation Reduction Act's rules on negotiated price cuts, according to Barclays, with a les...
Cantor's Louise Chen breaks down new Medicare drug pricing negotiations
Louise Chen, Cantor Fitzgerald, joins 'Power Lunch' to discuss Medicare drug priced ahead of Biden's news conference on the negotiations.
Oncology Market's Huge Potential Puts These Stocks in Focus
The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made mea...
Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases
Rare disease stocks have a difficult task. The rarer a disease is, the less public research goes into studying it.
Related Companies